Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 9.45M -92.1% |
| Revenue (ttm) | 2.50M +287.2% |
| Net Income | -67.62M |
| EPS | -1.66 |
| Shares Out | 44.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 878,383 |
| Open | 0.2052 |
| Previous Close | 0.2066 |
| Day's Range | 0.2001 - 0.2160 |
| 52-Week Range | 0.1980 - 5.1400 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 1.00 (+369.48%) |
| Est. Earnings | Nov 12, 2026 |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also deve... [Read more]
Financial Performance
In fiscal year 2026, Vistagen Therapeutics's revenue was $1.27 million, an increase of 161.11% compared to the previous year's $486,000. Losses were -$69.69 million, 35.5% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $1.0, which is an increase of 369.48% from the latest price.
News
SRX Global says adds investment in Onconetix
SRX Global Inc. (SRXH) announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (...
Vistagen presents data on fasedienol nasal spray at Psych Congress 2026
Vistagen (VTGN) presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company’s rapid-onset Phase...
Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24,...
Vistagen announces preliminary data from OLE of Palisade-4 Phase 3 study
Vistagen (VTGN) announced preliminary positive data from the open-label extension, OLE, portion of its PALISADE-4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a…
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months
Vistagen Therapeutics Transcript: AGM 2026
The meeting, held virtually, covered director elections, executive compensation, and auditor ratification. All proposals passed, with results to be reported in a forthcoming SEC filing.
Vistagen to Present at Psych Congress 2026
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signa...
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
Vistagen Therapeutics Earnings release: Q1 2027
Vistagen Therapeutics released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Vistagen Therapeutics Quarterly report: Q1 2027
Vistagen Therapeutics has published its Q1 2027 quarterly earnings report on August 14, 2026.
Vistagen announces topline results from fasedienol repeat dose study
Vistagen (VTGN) announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder. The three-arm, multicenter,...
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Pre...
SRX Global acquires stake in Vistagen
SRX Global (SRXH) announced that it has acquired a stake in Vistagen (VTGN). The company said it views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team…
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to dev...
Vistagen Therapeutics Proxy statement: Proxy filing
Vistagen Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Vistagen Therapeutics Proxy statement: Proxy filing
Vistagen Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Vistagen Therapeutics Transcript: Study update
The PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder did not meet primary or secondary endpoints in the overall population, but post-hoc analyses showed significant benefit in patients with very severe anxiety. Plans are underway to pursue a new registrational pathway using LSAS as the primary endpoint, supported by pooled data and favorable safety results.
Vistagen Therapeutics Press release: Study update
Vistagen Therapeutics issued a press release on June 30, 2026, disclosing material business information to investors.
Vistagen announces fasedienol did not achieve primary endpoint
Vistagen (VTGN) announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. In the overall trial population, fasedienol d...
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings release: Q4 2026
Vistagen Therapeutics released its Q4 2026 earnings on June 15, 2026, summarizing the period's financial results.
Vistagen Therapeutics Annual report: Q4 2026
Vistagen Therapeutics has published its Q4 2026 annual report on June 15, 2026.
Vistagen announces fasedienol achieves minimum patient exposures
Vistagen (VTGN) announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended un...
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...